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Abstract
Background: To update our experience with thoracic aortic stent-graft treatment over a 5-year
period, with special consideration for the occurrence and management of complications.
Methods: From December 2000 to June 2006, 52 patients with thoracic aortic pathologies
underwent endovascular repair; there were 43 males (83%) and 9 females, mean age 63 ± 19 years
(range 17–87). Fourteen patients (27%) were treated for degenerative thoracic aortic aneurysm,
12 patients (24%) for penetrating aortic ulcer, 8 patients (15%) for blunt traumatic injury, 7 patients
(13%) for acute type B dissection, 6 patients (11%) for a type B dissecting aneurysm; 5 patients
(10%) with thoraco-abdominal aortic aneurysms were excluded from the analyses. Fifteen patients
(32%) underwent emergency treatment. Overall, mean EuroSCORE was 9 ± 3 (median 15, range
3–19). All procedures were performed in the theatre under general anesthesia. All complications
occurring during hospitalisation were recorded. Follow-up protocol featured CT-A, and chest X-
rays 1, 4 and 12 months after intervention, and annually thereafter.
Results: Primary technical success was achieved in all patients; procedures never aborted because
of access difficulty. Conversion to standard open repair was never required. Mean duration of the
procedure was 119 ± 75 minutes (median 90, range 45–285). Mean blood loss was 254 mL (range
50–1200 mL). The mean length of the aorta covered by the SGs was 192 ± 21 mm (range 100–
360). The LSA was over-stented in 17 cases (17/47, 36%). Overall 30-day operative mortality was
6.4% (3/47). Major complications included pneumonia (n = 9), cerebrovascular accidents (n = 4),
arrhythmia (n = 4), acute renal failure (n = 3), and colic ischemia (n = 1). Overall, endoleak rate was
14%.
Conclusion: Although this report is a retrospective and not comparative analysis of thoracic
aortic repair, the combined minor and major morbidity rate was lower than previous reported to
results of either electively and emergency performed conventional repair.
Background
Endovascular treatment for aortic disease has emerged as
an alternative mode of treatment for thoracic aortic dis-
eases (TADs) that is particularly attractive for patients with
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for open surgery [1-6]. Because initial results have been
encouraging, this new therapy has been used more liber-
ally, and short-term results are well documented [1,4,5]
However, despite early promising clinical results, effect on
the long-term durability of the aortic repair have not been
yet established, they are associated with complications, as
are all surgical methods [7-9].
Here, we present our experience with TAA stent-graft (SG)
treatment, with special consideration for the occurrence
and management of complications.
Materials and methods
From December 2000 to June 2006, 52 patients with tho-
racic aortic pathologies underwent endovascular repair;
there were 43 males (83%) and 9 females, mean age 62 ±
19 years (range 17–87). Fourteen patients (27%) were
treated for degenerative thoracic aortic aneurysm, 12
patients (24%) for penetrating aortic ulcer, 8 patients
(15%) for blunt traumatic injury, 7 patients (13%) for
acute type B dissection, 6 patients (11%) for a type B dis-
secting aneurysm. Five additional patients who received
hybrid treatment (visceral revascularization and endovas-
cular thoracic SG) for thoraco-abdominal aortic aneu-
rysms were excluded from this series. Hence, 47 patients
wree considered for the retrospective analyses. Patient
data including procedure details, postoperative complica-
tions, secondary procedures, and mortality were collected.
Demographics and co-morbidities are listed in Table 1.
Fifteen patients (32%) underwent emergency treatment
because of blunt traumatic injury (n = 7), complicated dis-
section (n = 4), penetrating ulcer (n = 3), or ruptured
degenerative aneurysm. Eight patients (17%) had infrare-
nal aortic aneurysm repair in their medical history.
The Ishimaru classification were used to define the loca-
tion of the proximal neck of the lesion: "zone 0" involves
the innominate artery, "zone 1" the origin of the left com-
mon carotid artery, "zone 2" the origin of the left subcla-
vian artery, "zone 3" extends into the descending thoracic
aorta distally to the origin of the left subclavian artery,
"zone 4" involved the middle to the lower third of the
descending aorta: according to the Ishimaru classification,
the aortic pathology was located in the aortic arch (zone
1–2) in 12 patients, in proximal/mid-descending aorta
(zone 3) in 25 patients, and in the distal descending aorta
(zone 4) in 10 patients. Mean thoracic aortic aneurysm
diameter was 7.5 ± 2 cm (range 5.5–12), mean dissecting
aneurysm diameter was 7.3 ± 2 cm (range 6–9), and mean
ulcer diameter was 4.3 ± 0.8 cm (range 3.5–6.5).
Spiral CT or CT-angiography (CT-A) of the entire thoracic-
abdominal aorta was performed preoperatively in all
patients to determine the anatomical feasibility for the
endovascular procedure, aneurysm size, location, exten-
sion, and relationship between the aneurysm and signifi-
cant aortic branches such as the left subclavian artery
(LSA) and the visceral vessels (e.g celiac trunk, superior
mesenteric artery, renal arteries) (Figure 1). When elective
surgery was scheduled, all patients underwent spirometry,
echocardiography; a cardiologist was consulted to evalu-
ate eventual either pharmacologic stress testing or coro-
nary angiography. CT-A of the epiaortic trunks and
intracranial vessels were carried out in order to detect any
abnormalities (e.g. agenesia), stenosis, patency of the
anterior spinal artery, or previous ischemic areas.
All patients (or their relatives) were informed in detail
about the endovascular operation and gave written con-
sent. All procedures were performed in the theatre
equipped with a movable radiolucent surgical table com-
Table 1: Demographic data and co-morbidities
disease nr %
hypertension 34 72




previous aortic surgery 7 15
hypercholesterolemia 5 10
previous cardiovascular surgery 5 10
CVD 4 8
diabetes mellitus 4 8
BMI = body mass index; COPD = chronic obstructive pulmonary 
disease; IHD = ischemic heart disease CRF = chronic renal failure; 
CVD = cerebrovascular disease
Preoperative CT-A shows an 8-cm saccular aneurysm of the distal a ch (A, B); MIP reconstructions shows the involve-m nt of t e LSA (C)Figur  1
Preoperative CT-A shows an 8-cm saccular aneurysm of the 
distal arch (A, B); MIP reconstructions shows the involve-
ment of the LSA (C).Page 2 of 7
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suspended C-arm (Isocentric mobile C-arm-Siemens®;
Munich-Germany), under general anesthesia by a cardio-
vascular surgeon in close collaboration with an interven-
tional radiologist.
All patients received short-term prophylactic antibiotic
therapy (generally, vancomycin 2 gr b.i.d.) and heparini-
zation intraoperatively. All patients were prepared and
draped also for potential conversion to thoracotomy if it
became necessary. The patients were initially positioned
on their backs with the left shoulder slightly raised. Cardi-
opulmonary bypass (CPB) and a cell-saver (Compact-
Dideco®-Modena, Italy) were eventually available. Pro-
phylactic use of cerebrospinal fluid (CSF) drainage to pre-
vent spinal cord ischemia was not used. Surgical exposure
included the common femoral artery in 42 cases [monol-
aterally (n = 39) and bilaterally (n = 3)], an extra-perito-
neal approach for the external iliac artery (n = 3), a 10-
mm Dacron conduit end-to-side onto the common iliac
artery (n = 1), and transperitoneal approach (n = 1) dur-
ing an explorative laparptomy to repair associated multi-
ple liver fractures in a polytraumatized patients who
sustained traumatic aortic injury. Once we gained the
remote access, administration of 2500 IU heparin (Epso-
clar®-Biologici Italia Laboratories; Novate Milanese-IT)
was followed by insertion of the SG system. Calibrated
angiographic pigtail catheter (Cook Inc.®-Bloomington;
IN-USA) was placed in the ascending aorta, followed by a
digital subtraction angiography (DSA) to confirm the
beginning of the aneurysm, to mark the LSA (e.g. a 5F
catheter was preliminary advanced through a percutane-
ous left brachial artery access), and to determine the final
landing zone. Devices were then positioned with confirm-
atory DSA before deployment, to enable precise position-
ing. Dimensions of SG were determined on the basis of
contrast-enhanced spiral CT images and angiographic
images, and were oversized by 10% to 20%, depending on
the type of pathology; if multiple SGs wee needed,
implantation began with the distal device first and then
continued cephalad to the proximal end of the thoracic
lesion. A complete overlap of at least 2 cm was used, with
more overlap for severely angulated segments. Just before
the device was released, systolic arterial blood pressure
was lowered by nitro-prusside or B-blocker. Once
deployed, SG were assessed with a combination of DSA
and TEE to identify the presence of endoleak, evaluate the
degree of device apposition, and LSA revascularization
from the ipsilateral vertebral artery (Figure 2). An inflata-
ble balloon was eventually used to model the SG to the
aortic wall.
Several types of SG were used: Excluder/TAG [W.L. Gore &
ass.®-Flagstaff, AZ-USA (n = 24)], TX-1/TX-2 [Cook Inc®-
Bloomington, IN-USA (n = 12)], or Talent/Valiant
[Medtronic Inc®-Minneapolis, MN-USA (n = 11)] straight
tube devices. Simultaneous endovascular procedures
included AAA exclusion (n = 4), axillary artery stenting (n
= 3): in the former patients, both the thoracic and abdom-
inal lesions were successfully excluded. Abdominal aortic
SGs used were as following: Zenith [Cook Inc®-Blooming-
ton, IN-USA (n = 3)] or Excluder [W.L. Gore & ass.®-Flag-
staff, AZ-USA (n = 1)].
Patients were not routinely admitted to the surgical inten-
sive care unit postoperatively. A complete CT scan was
performed before the discharge in all patients to confirm
complete sealing of the aneurysm and identify any
endoleaks. A clinical neurological investigation was car-
ried out in case of neurological complications, with addi-
tional diagnostics imaging if required.
Technical success rate was defined as successful deploy-
ment of the SG without perigraft endoleak. Endoleak was
classified as primary (diagnosed within 30 days of
endovascular repair) or secondary (diagnosed more than
30 days after intervention) (Figure 3). All complications
occurring while the patient remained in the hospital or
later, were recorded. A >20% rise in renal parameters was
considered indication of renal complications. Mortality
rates were calculated at three intervals: during the in-hos-
pital stay (perioperative), 30-days after the operation
(early), and in follow-up (late).
The follow-up protocol featured spiral-CT or CT-A, plus
conventional 4-view chest X-rays to detect changes in SG
configuration at 1, 4 and 12 months after intervention,
and then annually. All films were reviewed by both an
Intraoperative preliminary DSA (A) confirm the presence of a "lusoria art ry" (arrow)Fig re 2
Intraoperative preliminary DSA (A) confirm the presence of 
a "lusoria artery" (arrow). Final DSA (B) confirmed the com-
plete exclusion of the aneurysm and the patency of the left 
common carotid artery (black arrow) and the re-filling of the 
LSA via the ipsilateral LVA (white arrow).Page 3 of 7
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the follow-up, DSA control was performed in patients
with persistent endoleak, stent migration, or aneurysm sac
enlargement.
Results
In all cases, the SG was placed successfully; neither proce-
dures aborted because of access difficulty, nor conversion
to standard open repair was necessary. The median delay
of the emergency procedure for traumatic injury from the
original accident was 95 ± 19 minutes (range 60–360),
whereas the overall median delay for the urgent proce-
dures was 108 ± 27 minutes (range 60–1440). Overall, the
mean duration of the procedure was 119 ± 75 minutes
(range 45–240). Median blood loss was 254 mL (range
50–1200 mL). The average total amount of contrast was
118 ± 50 mL (range 50–240). A total of 67 SGs were
implanted: 33 patients received a single SG, 10 patients
two SGs, and 4 patients three SGs. The mean length of the
aorta covered by the SGs was 192 ± 21 mm (range 100–
360), whereas mean SG diameter was 35 ± 4 mm (range
26–42). The LSA was over-stented in 17 cases.
Mortality
overall 30-day operative mortality was 6.4%, 3.1% in
those undergoing elective treatment and 13.3% in those
undergoing emergency treatment. In the elective group a
cause of death was an hemorrhagic shock due to a second-
ary rupture owing to an undetected endoleak, 6 days after
the procedure. In the emergency patients, we experienced
hemorrhagic shock (n = 1) due to rupture of a compli-
cated type B dissection, and a sudden irreversible cardiac
failure (n = 1). During follow-up (mean 18 months, range
2–60), two further patients died. The causes of death were
acute myocardial infarction (n = 1), and acute respiratory
failure (n = 1); mean interval was 11.6-months (range 48-
days-32-months). Overall, at 1, 3 and 5 years, survival for
elective and emergency cases were 89.3%, 83.3% and
79%, respectively.
Neurological sequelae
there was no paraparesis or paraplegia due to ischemia of
the spinal cord. Four patients (8.5%) developed cerebrov-
ascular events after the operation: we observed 2 cases of
transient ischemic events (TIA); and 2 strokes that
occurred 19 days after the intervention in a 62-years old
male patient with a zone 3 type B dissecting aneurysm and
was caused by recurrent peaks of hypertension that did
not respond to pharmacological therapy, and 2 days after
the intervention in a 79-tears male patient with a zone 2
aortic arch aneurysm. Patients with TIA did not developed
definitive neurological deficits.
Endoleaks
overall, endoleak rate was 14%. Conversion to open sur-
gery was never required. Early endoleaks were detected
before discharge in 2 patients: one type 1a endoleak and
1 type 2 endoleak from the LSA. The last one was success-
fully excluded by coils embolization at the origin of the
LSA. One type 1a endoleak developed after caudal migra-
tion of the SG, leaded to secondary rupture and finally
death. Late endoleaks occurred in 3 patients. We observed
1 type 1b endoleak that was treated by additional SG on
postoperative month 6, and two type 2 leaks from the LSA
(n = 1) that was sealed by coils embolization, and from an
intercostal artery (n = 1) that is still under survey with no
evidence of sac growth. New onset of endoleaks, at later
follow up, were not observed.
Follow-up CT-A showed late type Ib endoleak (arrow) after SG treatment of a type B dissecting aneurysm (A)igure 3
Follow-up CT-A showed late type Ib endoleak (arrow) after 
SG treatment of a type B dissecting aneurysm (A). Prelimi-
nary DSA (B) confirmed the re-perfusion of the false channel 
through a distal re-entry tear (arrow): additional SG was used 
to seal the aneurysm as confirmed by final DSA (C) with TEE 
control.Page 4 of 7
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the LSA was fully covered in 17 patients (36%). None of
the patients developed an upper arm ischemia. In 4 cases
in which the origin of the left common carotid artery
(LCA) was covered with a SG, a carotid-carotid PTFE
bypass was performed before stent-grafting. Preventive
bypass procedure to the LSA was performed in one case
only in a 79-years old male patient with a zone 1 arch
aneurysm; the preoperative CT-A revealed the occlusion of
the right vertebral artery, hence being at high risk of peri-
operative cerebrovascular accident we carried out an extra-
anatomical bypass to the LSA in addition to the carotid-
carotid bypass, before the SG procedure. Unfortunately,
the patient developed a major stroke (left part plus poste-
rior) two days after the intervention. In the remainder
cases, left upper arm ischemia did not develop, and retro-
grade flow through the ipsilateral vertebral artery (LVA)
was demonstrated by final DSA and postoperative duplex
examination. Retrograde reflux leaks from the subclavian
artery into the aorta occurred in 2 cases and were sealed by
coils.
Other complications
overall, the most common complication was pneumonia
(n = 8), followed by arrhythmia [atrial fibrillation (n = 3)
and atrial flutter (n = 1]). Six patients (13%) developed
renal impairment [(early (n = 3), late (n = 3)]. Temporary
hemofiltration or dialysis was necessary in 2 patients. Two
patients demonstrated new, clinically silent splenic infarc-
tions on the postoperative CT but did not develop abscess
or subsequent infectious complications; both lesions
resolvedcompletely. Colic ischemia developed in a 74-
year male patient on day twenty-seventh, postoperatively
and required an Hartman intervention: he did well and
was discharged without further complication. Among
minor complications, the most frequent was post-implant
syndrome (PIS) that developed in 7 patients (15%). No
patients had retrograde acute ascending thoracic dissec-
tions. Thoracic lesion shrinkage, defined as a sac reduc-
tion of 5 mm at least after 12-months CT-A follow-up
control, was observed in 22 patients (47%).
Discussion
Mortality is the most important criterion in appraising the
results of TAA treatment. Conventional intervention car-
ries a mortality rate that ranges between 3% and 26%, up
to 75% for emergency repair [10,11]. In their largest
series, Stanford equipe reported a perioperative mortality
of 9% [12]. The 6% thirty-day mortality we attained with
endovascular repair, is similar to previous reports of pro-
cedure-related mortality in patients undergoing endovas-
cular treatment of TAA and dissections and the benefits of
the intraluminal approach are apparent [2,4,7,9]. Moreo-
ver, the 13% thirty-day mortality in our emergency cases
are quite encouraging: considering that all the procedures
were performed in high-risk patients, we believe that this
early mortality rate is acceptable. It is interesting to note
that patients with TAD who required emergent treatment
had a procedure related mortality lower than reported,
although most of the patients had active bleeding at pres-
entation. This result suggest that, even among patients
with the highest risk, endovascular repair can be under-
taken with acceptable mortality. Given the high mortality
in patients who undergo emergent open repair, these
patients would seem to benefit most from endovascular
treatment. Indeed, all the late deaths in our cohort were
not related to the SG procedure; in order to reduce mortal-
ity and morbidity rates, careful selection criteria must be
followed when treating patients endovascularly: using
objective criteria could help in selecting patients for
endovascular treatment [13].
Surgeons have often focused on death, bleeding, and par-
aplegia as the major adverse outcomes of thoracic aortic
surgery [1,2,4-6,12]. Stroke may not be adequately appre-
ciated as a common sequel of descending aortic opera-
tions. Most clinical reports on aortic surgical procedures
simply state an overall incidence of stroke without specific
analysis of this complication [14,15]. In our series, stroke
was found to be disturbingly frequent after aortic surgery.
In multivariable analysis, a number of risk factors were
found to be predictive of stroke for open surgery: these
included a history of diabetes mellitus (possibly caused by
chronic damage to the cerebral microvasculature), and
emergency surgery; in our experience, all but one cere-
brovascular accidents were embolic-technically related,
and appeared to be caused by the manipulation of wires
and catheters in an atherosclerotic aortic arch [14]. Thus,
meticulous technique must be used during device deploy-
ment to avoid atheroembolic cerebrovascular events.
Spinal cord ischemia and postoperative neurologic deficit
with surgical repair of degenerative aneurysms and tho-
raco-abdominal aneurysms are believed to be multifacto-
rial in etiology. Their occurrence is influenced by the
duration and severity of the ischemic insult, the neuronal
metabolic rate during this ischemic period, the postoper-
ative hypotension, and a subsequent reperfusion injury
[2,11,16,17]. In-addition, the extent of the aneurysm
involvement with the thoracic aorta has been shown to
influence the expected rate of neurologic deficit after open
thoracic aortic aneurysm and thoraco-abdominal repair
[16]. Despite many improvements in the technique and
adjuncts, the rates of paralysis in conventional open sur-
gery range from 1.5% to 19% in high-volume centers
[10,11,16-19]. However, since a large number of intercos-
tal arteries are acutely occluded even in endovascular
repair, especially when long SG are implanted (a maxi-
mum of 360 mm in our patients), paralysis can still occur.
In our own patients, there has been no case of paralysis upPage 5 of 7
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racic aorta was 195 mm, which means that 4 to 5 pairs of
intercostal arteries were occluded at least. The aortic seg-
ment from T7 to T11, regarded as particularly sensitive,
was covered with SG in 10 of our patients.
Because of the absence of aortic cross-clamping and reper-
fusion, endovascular SG repair of the descending thoracic
aorta may lower the incidence of spinal cord ischemia.
Those cases with TAA stent-grafting with concomitant
open AAA repair also undergo a period of aortic cross-
clamping, potentially causing an even more severe initial
spinal cord ischemia as well as adding an element of
reperfusion injury to the ischemic insult, being associated
with an increased risk of paraplegia, since the absence of
the normal lumbar or ilio-lumbar arteries sacrificed by
AAA surgery may place these candidates at an increased
risk for spinal cord ischemia [11,20-23]. We noted no par-
aplegia or paraparesis, although the distal thoracic aorta
was stented in eight patients with previous abdominal
aortic surgery, and four patients had concomitant
endovascular aortic multilevel disease.
Although in the initial steps of previous published stud-
ies, endoleaks in the thorax seemed markedly less signifi-
cant than of aneurysms of the infrarenal aorta, it soon
became obvious that endoleaks after thoracic endovascu-
lar therapy are a serious complication [1,4,7,8,12]. Degen-
erative disease and atherosclerotic aneurysm formation of
the thoracic aorta are diffuse and progressive in character,
often involving the entire thoracic aorta, but changes
within the proximal and distal neck caused by disease pro-
gression have been reported causing type 1 endoleak [7].
Neck dilatation after endovascular aneurysm repair has
previously been recognized in 2 patients by a group at
Stanford University. In our series 2 patients displayed
neck dilatation [12]. Our policy in treating type Ib
endoleaks was to implant a cuff at the endoleak site. These
late complications show the necessity of mandatory life-
long follow-up. Finally, disease progression proximally or
distally, especially in patients with diffuse degenerative
aneurysms, may result in slow enlargement of the landing
zones, loss of fixation, and sac pressurization [2,7]. Iso-
lated cases of secondary rupture after SG have been
described in many reports. In all of these cases, technical
errors of untreated primary or secondary endoleaks could
be incriminated. In this series post-procedural rupture was
observed in one patient. Multiple factors may have con-
tributed to these late endoleaks. The association between
action of vector forces in SG and the often severe tortuos-
ity in the thoracic aorta might induce even stronger vector
forces after aneuryms repair.
Renal failure (RF) has been reported as one of the leading
cause of postopretaive death following conventional
descending aneurysm and thoraco-abdominal repair; also
endovascular repair involved new potential risks specific
to the procedure, which may be associated with a substan-
tial rate of postoperative RF [23]: the incidence of long-
term RF following endovascular aortic aneurysm exclu-
sion is poorly documented in the literature; the incidence
of postoperative RF ranged between 2.5% and 6.6% in
previous reported series [24]. In the present study, tran-
sient perioperative RF occurred in 13% of patients; more-
over, it has been noted a trend toward this being a more
common event in those patients with pre-existing RF
[18,24,25]. We identified a 17% prevalence of preopera-
tive RF in our own population undergoing endovascular
repair. Our incidence of renal complications is similar
than rates reported by others [24]. Most likely the etiology
is multifactorial, resulting from a combination of
mechanical, atheroembolic and contrast related contribu-
tors. In particular, the relationship between contrast type
and volume and renal function has been established [25].
Contrast induced renal insufficiency is reversible, yet in
our patients, the noted creatinine rise was permanent in
only 1 case of those patients who had deterioration of
renal function: this suggests factors other than contrast
exposure alone as contributory, suggesting atheroembolic
sequelae. Strategies may be adopted to minimize the like-
lihood of adverse renal effects associated with aortic SG at
all stages of evaluation and intervention. While our rou-
tine practice involves the use of non-ionic contrast agents
in association with vigorous hydration and use of osmotic
diuretics, we have greatly reduced our reliance upon angi-
ography employing iodinated contrast agents in our
patients with RF.
Conclusion
Although this report is a retrospective and not compara-
tive analysis of thoracic aortic repair, the combined minor
and major morbidity rate was lower than previous
reported to results of either electively and emergency per-
formed conventional repair.
Despite the favorability of these findings, complications
unique to endovascular repair of descending thoracic aor-
tic lesions (eg, RF, stroke, leakage) did occur. These com-
plications in part reflect the results of an evolving
technology that involves a requisite learning curve and
developmental issues. A reduction in these method-
related complications can in all probability be achieved
only by improved SG and optimal patient selection and
matching.
In addition to the usual concerns of death, bleeding, and
paraplegia, surgeons must consider stroke heavily when
deciding to operate on the thoracic aorta. Meticulous tech-
nique must be used during device deployment to avoid
atheroembolic cerebrovascular events.Page 6 of 7
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patients being considered for endovascular aneurysm
repair. It should not be considered a contraindication to
the evaluation or management of these patients provided
that care is taken to pursue a strategy that minimizes the
risk of renal injury.
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